59
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration

, , , , , , & show all
Pages 3415-3423 | Published online: 19 Oct 2016

References

  • SemeraroFMorescalchiFDuseSAflibercept in wet AMD: specific role and optimal useDrug Des Devel Ther20137711722
  • PanosGDGatzioufasZPetropoulosIKEffect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degenerationDrug Des Devel Ther20137565569
  • TranosPVacalisAAsteriadisSResistance to antivascular endothelial growth factor treatment in age-related macular degenerationDrug Des Devel Ther20137485490
  • KwakNOkamotoNWoodJMCampochiaroPAVEGF is major stimulator in model of choroidal neovascularizationInvest Ophthalmol Vis Sci200041103158316410967078
  • GehlbachPDemetriadesAMYamamotoSPeriocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrierHum Gene Ther200314212914112614564
  • HeYSmithSKDayKAAlternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activityMol Endocrinol199913453754510194760
  • KendallRLWangGThomasKAIdentification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDRBiochem Biophys Res Commun199622623243288806634
  • BainbridgeJWMistryADe AlwisMInhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1Gene Ther20029532032611938451
  • HondaMSakamotoTIshibashiTInomataHUenoHExperimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degenerationGene Ther200071197898510849558
  • LaiCMBrankovMZaknichTInhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularizationHum Gene Ther200112101299131011440623
  • LaiYKShenWYBrankovMPotential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapyGene Ther200291280481312040462
  • NozakiMRaislerBJSakuraiEDrusen complement components C3a and C5a promote choroidal neovascularizationProc Natl Acad Sci U S A200610372328233316452172
  • BoraNSKaliappanSJhaPComplement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor HJ Immunol200617731872187816849499
  • BoraNSKaliappanSJhaPCD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degenerationJ Immunol200717831783179017237428
  • BoraNSJhaPLyzogubovVVRecombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in miceJ Biol Chem201028544338263383320736175
  • HagemanGSLuthertPJVictor ChongNHAn integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degenerationProg Retin Eye Res200120670573211587915
  • YatesJRSeppTMatharuBKComplement C3 variant and the risk of age-related macular degenerationN Engl J Med2007357655356117634448
  • JohnsonLVLeitnerWPStaplesMKAndersonDHComplement activation and inflammatory processes in Drusen formation and age related macular degenerationExp Eye Res200173688789611846519
  • AndersonDHMullinsRFHagemanGSJohnsonLVA role for local inflammation in the formation of drusen in the aging eyeAm J Ophthalmol2002134341143112208254
  • HuangYQiaoFAtkinsonCA novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injuryJ Immunol2008181118068807619017999
  • Fridkis-HareliMStorekMMazsaroffIDesign and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseasesBlood2011118174705471321860027
  • RohrerBLongQCoughlinBA targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degenerationInvest Ophthalmol Vis Sci20095073056306419264882
  • RohrerBCoughlinBBandyopadhyayMHolersVMSystemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularizationJ Ocul Pharmacol Ther201228440240922309197
  • BandaNKLevittBGlogowskaMJTargeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in miceJ Immunol200918395928593719828624
  • HuXTomlinsonSBarnumSRTargeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAENeurosci Lett20125311353923079547
  • SongHHeCKnaakCComplement receptor 2-mediated targeting of complement inhibitors to sites of complement activationJ Clin Invest2003111121875188512813023
  • LiWChenSMaMQianJMaXComplement 5b-9 complex-induced alterations in human RPE cell physiologyMed Sci Monit2010161BR17BR2320037481